Moreover, as YWHAE loss has been reported in gastric cancers and is associated with proteasome-inhibitor resistance in multiple myeloma (60,61), CHK1i treatment may be a viable option for patients with these cancers. Here, YWHAE is linked to AL amyloidosis.